Skip to main content
. 2018 Oct 1;2018(10):CD002252. doi: 10.1002/14651858.CD002252.pub4

Comparison 5. Any antihypertensive versus methyldopa (subgrouped by class of drug).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Severe hypertension 11 638 Risk Ratio (M‐H, Fixed, 95% CI) 0.70 [0.56, 0.88]
1.1 Beta blocker versus methyldopa 9 592 Risk Ratio (M‐H, Fixed, 95% CI) 0.74 [0.59, 0.93]
1.2 Calcium channel blockers versus methyldopa 2 46 Risk Ratio (M‐H, Fixed, 95% CI) 0.23 [0.04, 1.22]
2 Proteinuria/pre‐eclampsia 11 997 Risk Ratio (M‐H, Random, 95% CI) 0.78 [0.58, 1.06]
2.1 Beta blocker versus methyldopa 10 903 Risk Ratio (M‐H, Random, 95% CI) 0.82 [0.58, 1.16]
2.2 Calcium channel blockers versus methyldopa 1 94 Risk Ratio (M‐H, Random, 95% CI) 0.66 [0.34, 1.27]
3 Total reported fetal or neonatal death (including miscarriage) 22 1791 Risk Ratio (M‐H, Random, 95% CI) 0.77 [0.52, 1.14]
3.1 Beta blocker versus methyldopa 16 1280 Risk Ratio (M‐H, Random, 95% CI) 0.80 [0.43, 1.50]
3.2 Calcium channel blocker versus methyldopa 4 251 Risk Ratio (M‐H, Random, 95% CI) 0.31 [0.04, 2.65]
3.3 Beta blockers or calcium channel blockers versus methyldopa 1 240 Risk Ratio (M‐H, Random, 95% CI) 0.76 [0.46, 1.27]
3.4 Ketanserin versus methyldopa 1 20 Risk Ratio (M‐H, Random, 95% CI) 3.0 [0.14, 65.90]
4 Small‐for‐gestational age 7 597 Risk Ratio (M‐H, Random, 95% CI) 0.79 [0.52, 1.20]
4.1 Beta blocker versus methyldopa 6 577 Risk Ratio (M‐H, Random, 95% CI) 0.84 [0.54, 1.31]
4.2 Calcium channel blocker versus methyldopa 1 20 Risk Ratio (M‐H, Random, 95% CI) 0.4 [0.10, 1.60]
5 Preterm birth (< 37 weeks) 11 835 Risk Ratio (M‐H, Random, 95% CI) 0.91 [0.68, 1.22]
5.1 Beta blocker versus methyldopa 8 694 Risk Ratio (M‐H, Random, 95% CI) 0.90 [0.62, 1.29]
5.2 Calcium channel blocker versus methyldopa 3 141 Risk Ratio (M‐H, Random, 95% CI) 0.84 [0.44, 1.64]
6 Severe pre‐eclampsia 1 311 Risk Ratio (M‐H, Random, 95% CI) 1.15 [0.56, 2.33]
6.1 Beta blocker versus methyldopa 1 311 Risk Ratio (M‐H, Random, 95% CI) 1.15 [0.56, 2.33]
7 Eclampsia 1 92 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
7.1 Calcium channel blockers versus methyldopa 1 92 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Need for additional antihypertensive drug/s 13 1081 Risk Ratio (M‐H, Random, 95% CI) 0.73 [0.47, 1.13]
8.1 Beta blocker versus methyldopa 10 853 Risk Ratio (M‐H, Random, 95% CI) 0.76 [0.45, 1.28]
8.2 Calcium channel blocker versus methyldopa 3 228 Risk Ratio (M‐H, Random, 95% CI) 0.62 [0.30, 1.28]
9 Elective delivery (induction of labour + elective caesarean section) 7 655 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.90, 1.09]
9.1 Beta blocker versus methyldopa 5 453 Risk Ratio (M‐H, Random, 95% CI) 1.01 [0.90, 1.12]
9.2 Calcium channel blocker versus methyldopa 2 202 Risk Ratio (M‐H, Random, 95% CI) 1.03 [0.65, 1.63]
10 Caesarean section 13 1330 Risk Ratio (M‐H, Random, 95% CI) 0.84 [0.74, 0.95]
10.1 Beta blocker versus methyldopa 10 972 Risk Ratio (M‐H, Random, 95% CI) 0.96 [0.81, 1.13]
10.2 Calcium channel blocker versus methyldopa 2 118 Risk Ratio (M‐H, Random, 95% CI) 0.66 [0.38, 1.16]
10.3 Beta blocker or calcium channel blocker versus methyldopa 1 240 Risk Ratio (M‐H, Random, 95% CI) 0.70 [0.57, 0.86]
11 Induction of labour 3 452 Risk Ratio (M‐H, Random, 95% CI) 1.14 [0.89, 1.45]
11.1 Beta blocker versus methyldopa 1 120 Risk Ratio (M‐H, Random, 95% CI) 1.0 [0.65, 1.53]
11.2 Calcium channel blocker versus methyldopa 1 92 Risk Ratio (M‐H, Random, 95% CI) 1.09 [0.75, 1.57]
11.3 Beta blocker or calcium channel blocker versus methyldopa 1 240 Risk Ratio (M‐H, Random, 95% CI) 1.54 [0.89, 2.64]
12 Antenatal hospital admission 2 275 Risk Ratio (M‐H, Random, 95% CI) 0.56 [0.17, 1.86]
12.1 Beta blocker versus methyldopa 2 275 Risk Ratio (M‐H, Random, 95% CI) 0.56 [0.17, 1.86]
13 Placental abruption 1 173 Risk Ratio (M‐H, Random, 95% CI) 2.02 [0.19, 21.90]
13.1 Beta blocker versus methyldopa 1 173 Risk Ratio (M‐H, Random, 95% CI) 2.02 [0.19, 21.90]
14 Maternal side‐effects 6 412 Risk Ratio (M‐H, Random, 95% CI) 0.22 [0.02, 2.09]
14.1 Beta blocker versus methyldopa 5 302 Risk Ratio (M‐H, Random, 95% CI) 0.22 [0.02, 2.09]
14.2 Calcium channel blockers versus methyldopa 1 110 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
15 Changed/stopped drugs due to maternal side‐effects 4 272 Risk Ratio (M‐H, Random, 95% CI) 2.80 [0.12, 67.91]
15.1 Beta blocker versus methyldopa 4 272 Risk Ratio (M‐H, Random, 95% CI) 2.80 [0.12, 67.91]
16 Admission to neonatal or intensive care nursery 6 688 Risk Ratio (M‐H, Random, 95% CI) 0.95 [0.72, 1.27]
16.1 Beta blocker versus methyldopa 4 571 Risk Ratio (M‐H, Random, 95% CI) 0.92 [0.67, 1.25]
16.2 Calcium channel blocker versus methyldopa 2 117 Risk Ratio (M‐H, Random, 95% CI) 1.22 [0.56, 2.64]
17 Respiratory distress syndrome 1 118 Risk Ratio (M‐H, Random, 95% CI) 0.86 [0.31, 2.40]
17.1 Beta blocker versus methyldopa 1 118 Risk Ratio (M‐H, Random, 95% CI) 0.86 [0.31, 2.40]
18 Neonatal hypoglycaemia 5 439 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.47, 2.05]
18.1 Beta blocker versus methyldopa 5 439 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.47, 2.05]
19 Neonatal bradycardia 2 146 Risk Ratio (M‐H, Random, 95% CI) 3.0 [0.12, 72.18]
19.1 Beta blocker versus methyldopa 2 146 Risk Ratio (M‐H, Random, 95% CI) 3.0 [0.12, 72.18]
20 Neonatal jaundice 2 146 Risk Ratio (M‐H, Random, 95% CI) 1.05 [0.48, 2.29]
20.1 Beta blocker versus methyldopa 2 146 Risk Ratio (M‐H, Random, 95% CI) 1.05 [0.48, 2.29]